These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 8521709)

  • 1. Enlarged follicles in women using oral contraceptives.
    Broome M; Clayton J; Fotherby K
    Contraception; 1995 Jul; 52(1):13-6. PubMed ID: 8521709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian function during low-dose oral contraceptive use.
    Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
    Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian activity suppression by two different low-dose triphasic oral contraceptives.
    van der Does J; Exalto N; Dieben T; Bennink HC
    Contraception; 1995 Dec; 52(6):357-61. PubMed ID: 8749599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
    Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
    Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development.
    Young RL; Snabes MC; Frank ML; Reilly M
    Am J Obstet Gynecol; 1992 Sep; 167(3):678-82. PubMed ID: 1530022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive.
    Jain JK; Ota F; Mishell DR
    Contraception; 2000 Mar; 61(3):195-8. PubMed ID: 10827333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound evaluation of ovarian activity under oral contraceptives.
    Hoogland HJ; Skouby SO
    Contraception; 1993 Jun; 47(6):583-90. PubMed ID: 8334892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on ovarian function in users of the progestagen only contraceptive pill.
    Tayob Y; Guillebaud J; Adams J; Jacobs HS
    J Obstet Gynaecol (Lahore); 1986 Apr; 6 Suppl 2():S91-5. PubMed ID: 12315277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen.
    Wilson ES; Cruickshank J; McMaster M; Weir RJ
    Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women.
    Gaspard UJ; Deville JL; Dubois M
    Curr Med Res Opin; 1983; 8(6):395-404. PubMed ID: 6406157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.
    Masson S; Franssen E; Hilditch JR; Powell MG
    Contraception; 1993 Jan; 47(1):43-54. PubMed ID: 8436001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial.
    Weber-Diehl F; Lehnert J; Lachnit U
    Contraception; 1993 Oct; 48(4):291-301. PubMed ID: 8222658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.